Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Department of Health Administration and Health Policy, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, USA.
Addict Behav. 2025 Jan;160:108180. doi: 10.1016/j.addbeh.2024.108180. Epub 2024 Sep 26.
To characterize derived psychoactive cannabis product (DPCP) perceptions and use among US young adults.
We analyzed 2023 survey data among 4,031 young adults (ages 18-34), comprising ∼ 50 % reporting past-month cannabis use. Multivariable regressions examined sociodemographics, cannabis use, and DPCP risk perceptions in relation to: 1) past-month DPCP use (yes/no), 2) past-month number of DPCP use days, and 3) among those reporting no past-month DPCP use, future likelihood of DPCP use.
In this sample (M = 26.3, 59.8 % female, 64.9 % White, 19.4 % Hispanic), DPCP awareness (67.5 %), lifetime use (41.7 %), and past-month use (24.4 %) differed by past-month cannabis use versus nonuse (87.0 % vs 48.8 %, 68.7 % vs 15.9 %, 45.6 % vs 4.2 %, respectively). Those aware learned about them mainly from friends/family (44.5 %) and believed DPCPs were required to be tested and approved to be safe (70.3 %) or were approved by the US Food and Drug Administration (59.0 %). Those who ever used DPCPs most often used delta-8 (69.7 %) and delta-9 (44.4 %) THC and for curiosity (55.5 %), belief of federal legality (34.1 %), and friends' suggestion (34.0 %). Correlates of past-month DPCP use, using more frequently, and higher likelihood of future use were: lower DPCP perceived harm and higher perceived addictiveness. Living where non-medical cannabis was illegal, higher perceived social acceptability, being Black (vs. White), and past-month cannabis use were also correlated with past-month use (but not frequency) and future likelihood of use.
Efforts are needed to better understand DPCPs' risks and correct consumer misperceptions. Relatedly, DPCP regulation, including marketing and distribution, is crucial.
描述美国年轻成年人对衍生致幻大麻产品（DPCP）的认知和使用情况。
我们分析了 2023 年 4031 名年轻成年人（年龄在 18-34 岁之间）的调查数据，其中约 50%报告过去一个月内有使用大麻。多变量回归分析了社会人口统计学、大麻使用情况以及 DPCP 风险认知与以下因素之间的关系：1）过去一个月 DPCP 使用情况（是/否）；2）过去一个月 DPCP 使用天数；3）在过去一个月内没有使用 DPCP 的人群中，未来使用 DPCP 的可能性。
在该样本中（M=26.3，59.8%为女性，64.9%为白人，19.4%为西班牙裔），DPCP 的知晓率（67.5%）、终身使用率（41.7%）和过去一个月使用率（24.4%）在过去一个月使用大麻与不使用大麻的人群之间存在差异（87.0%比 48.8%，68.7%比 15.9%，45.6%比 4.2%）。那些知晓 DPCP 的人主要从朋友/家人那里了解到它们（44.5%），并认为 DPCP 需要经过测试和批准才能安全使用（70.3%）或获得美国食品和药物管理局的批准（59.0%）。那些曾经使用过 DPCP 的人最常使用 delta-8（69.7%）和 delta-9（44.4%）THC，原因是出于好奇（55.5%）、相信联邦合法性（34.1%）和朋友的建议（34.0%）。过去一个月使用 DPCP、使用频率更高和未来更有可能使用 DPCP 的相关因素是：感知到的 DPCP 危害较低和感知到的成瘾性较高。生活在非医用大麻非法的地方、感知到的社会可接受性较高、是黑人（与白人相比）以及过去一个月使用大麻与过去一个月使用 DPCP（但与使用频率无关）和未来使用 DPCP 的可能性较高有关。
需要努力更好地了解 DPCP 的风险并纠正消费者的误解。与此相关的是，DPCP 的监管，包括营销和分销，至关重要。
